AXQ Capital’s Celldex Therapeutics CLDX Stock Holding History

AXQ Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,237	Closed	-$230K	–	1046
2026 Q1	$230K	Buy	+7,237	New	+$197K	0.03%	690

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AXQ Capital's CLDX Position: Q2 2026 in Review

AXQ Capital sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 7,237 shares — an estimated $230K sold.

AXQ Capital first reported a position in CLDX in Q1 2026 and held it in 1 quarter. The position peaked at $230K in Q1 2026. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

AXQ Capital reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
AXQ Capital sold 7,237 Celldex Therapeutics shares in Q2 2026, an estimated $230K.
AXQ Capital first reported a position in Celldex Therapeutics in Q1 2026 and held it in 1 quarter.
AXQ Capital's Celldex Therapeutics position peaked at $230K in Q1 2026.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.